Drug Trial Radar · NCT01282619
Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Jan 25, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
390
Planned (sponsor's estimate)
Start
May 2010
Primary completion
Jun 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- Shandong Luye Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety and efficacy of Huperzine A sustained release tablets in patients with mild to moderate Alzheimer's Disease.
Conditions
- Alzheimer's Disease
Interventions
Huperzine ADrug
Sustained-Release Tablet, 400µg once a day, 24 weeks
huperzine ADrug
Tablet, 200µg twice a day, 24 weeks
PlaceboDrug
placebo orally twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Alzheimer's Disease Assessment Scale - Cognitive SubscaleTime frame: week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.